Gilead Sciences has announced $24 million in grants to help communities most impacted by the HIV epidemic and COVID-19 pandemic. 

Awarded through the company’s Zeroing In: Ending the HIV Epidemic program, the grants will support 116 organizations around the world focused on advancing at least one of three focus areas: comprehensive HIV innovation, digital health innovation and community outreach, and education. Gilead provides support to organizations whose programs align with international and country-specific Ending the HIV Epidemic goals, including local community programming and coalition-led proposals from organizations collaborating to end the HIV epidemic in their respective city, state, country, or region. 

“While the HIV community has made tremendous progress toward ending the HIV epidemic, the COVID-19 pandemic created barriers and amplified health inequities in the most marginalized communities,” said Alex Kalomparis, Gilead Sciences’ senior vice president, public affairs. “We are working with organizations that will reach under-resourced communities and support them to find innovative, effective solutions. Zeroing In programs aim to increase access to HIV care and services and build on Gilead’s efforts to help end the epidemic for everyone, everywhere.” 

For a complete list of grant recipients, see the Gilead Sciences website.

(Photo Credit: Getty Images/PeopleImages)